請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34952完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 吳金冽 | |
| dc.contributor.author | Yu-Da Chen | en |
| dc.contributor.author | 陳昱達 | zh_TW |
| dc.date.accessioned | 2021-06-13T06:37:29Z | - |
| dc.date.available | 2006-01-27 | |
| dc.date.copyright | 2006-01-06 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-10-04 | |
| dc.identifier.citation | Alvarez B, Garrido E, Garcia-Sanz JA, Carrera AC. (2003). Phosphoinositide 3-kinase activation regulates cell division time by coordinated control of cell mass and cell cycle progression rate. J Biol Chem 278: 26466-73.
Araki E, Lipes MA, Patti ME, Bruning JC, Haag BL, Johnson RS. (1994). Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372: 186-90. Bai MZ, Pollman MJ, Inishi Y , Gibbons GH. (1999) . Regulation of vascular smooth muscle cell apoptosis. Modulation of bad by a phosphatidylinositol 3-kinase-dependent pathway. Circ Res 85:229–237. Baker J, Liu JP, Robertson EJ, Efstradiatis A. (1993). Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73–82. Baserga R. (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249–252. Baserga R, Peruzzi F. & Reiss K. (2003). The IGF-1 receptor in cancer biology. Int. J. Cancer 107: 873–877. Brissenden JE, Ullrich A, Francke U. (1984). Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature 310: 781–784. Brunet A, Bonni A, Zigmond MJ. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857–868. Byrd JC, Devi GR, de Souza AT, Jirtle RL, MacDonald RG. (1999) . Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 274: 24 408–24 416. Byrne AT, Southgate J, Brison DR, Leese HJ. (2002). Regulation of apoptosis in the bovine blastocyst by insulin and the insulin-like growth factor (IGF) super family. Mol Reprod Dev 62: 489-95. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, Brechot C. (1988). Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48: 6844–6849. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE. (2003). Two new substrates in insulin signaling. IRS5/DOK4 and IRS6/DOK5. J Biol Chem 278: 25323-25330. Cereghini S, Blumenfeld M, Yaniv M. (1988). A liver-speciflc factor essential for albumin transcription differs between differentiated and dedifferentiated rat hepatoma cells. Genes & Dev 2: 957–74. Chappel VL, Le LX, LaGrone L, Mileski WJ. (2000). Stat proteins play a role in tumor necrosis factor alpha gene expression. Shock 14: 400-2. Chirillo P, Falco M, Puri P L, Artini M, Balsano C, Levrero M, Natoli G. (1996). Hepatitis B virus pX activates NF- B-dependent transcription through a Raf-independent pathway. J. Virol 70: 641-646. Chrysis D, Calikoglu AS, Ye P,D'Ercole AJ. (2001) .Insulin-like growth factor-I overexpression attenuates cerebellar apoptosis by altering the expression of Bcl family proteins in a developmentally specific manner. J Neurosci 21:1481–1489. Chung TW, Lee YC, Ko JH, Kim CH. ( 2003 ). Hepatitis B Virus X Protein Modulates the Expression of PTEN by Inhibiting the Function of p53, a Transcriptional Activator in Liver Cells. Cancer Res. Jul 1;63(13):3453-8. Cohen, P. (1992). Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endo Met 75: 1046–1053 Constancia M, Hemberger M, Hughes J. (2000). Placenta-specific IGF-II is a major modulator of placenta and fetal growth. Nature 417:945–948. Costa RH, Grayson DR, Darnell JE Jr. (1989). Multiple transthyretin and α1-antitrypsin genes. Mol Cell Biol 9: 1415–25. Courtois G, Morgan JG, Campbell LA., Fourel G, Crabtree GR. (1987).Interaction of a liver-specific nuclear factor with the fibrinogen and α1-antitrypsin promoters. Science 238: 688–92. Crews CM, Erikson RL. (1993). Extracellular signals and reversible protein phosphorylation. What to Mek of it all. Cell 74: 215–217. d'Arville CN, Nouri-Aria KT, Johnson P, Williams R. (1991). Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology 13: 310–315. Dafgard E, Bajaj M, Honegger AM, Pitts J, Wood S, Blundell T. ( 1985 ) . The conformation of insulin-like factors : Relationships with insulins. J Cell Sci Suppl 3:53-64 Deane NG, Parker MA, Aramandla R, DiehlL, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD (2001). Hepatocellular Carcinoma Results from Chronic Cyclin D1 Overexpression in Transgenic Mice. Cancer Research 61:5389-5395. DeChiara TM, Efstratiadis A, Robertson E. (1990). A growth deficiency phenotype in heterozygous mice carrying an insulin- like growth factor II gene disrupted by targeting. Nature 345:78–80. DeChiara TM, Robertson EJ, Efstratiadis A. (1991). Parental imprinting of themouse insulin-like growth factor II gene. Cell 64:849–859. DeMeyts P, Whittaker J. (2002). Structural biology of insulin and IGF-1 receptors: implications for drug design. Nature Rev. Drug Discov. 1:769–783. De Souza AT, Yamada T, Mills JJ, Jirtle RL. (1997). Imprinted genes in liver carcinogenesis. FASEB J 11:60–67. Devi GR, De Souza AT, Byrd JC, Jirtle RL, MacDonald RG. (1999). Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. Cancer Res 59:4314–4319. Dull TJ, Gray A, Hay.ick JS. (1984). Insulin-like growth factor II precursor gene organization in relation to insulin gene family. Nature 310:777–781. Elmlinger MW. (2001). In vivo expression of insulin-like growth factor-binding protein in human gliomas increases with tumor grade. Endocrinoogy 142:1652–1658. Firth SM, Baxter RC. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23:824–854. Galvan V, Logvina A, Sperandio S, Ichijo H, Bredesen DE. (2003). Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J Biol Chem 278:13325-32. Gong Z, Ju B, Wan H. (2001).Green fluorescent protein (GFP) transgenic fish and their applications.Genetica 111:213-25 Grimberg A. (2000). P53 and IGFBP-3: apoptosis and cancer protection. Mol Gene Metab 70: 85–98. Girnita L, Girnita A, Larsson O. (2003). Mdm2-dependent ubiquination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 100:8247-52. Gottlieb TM. (1996). Oren M. p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287:77-102. Haeften TW, Twickler TB. (2004). Insulin-like growth factors and pancreas beta cells. Eur J Clin Invest 34(4):249-55. Hardon E, Frain M, Paonessa G, Cortese R. (1988). Two distinct factors interact with the promoter regions of several liver specific genes. EMBO J7: 1711–9. Harper ME, Franchini G, Love J, et al. (1983). Chromosomal sublocalization of human c-myb and c-fes cellular oncogenes. Nature 304:169–171 Harris TM, Rogler LE, Rogler CE. (1998). Reactivation of the maternally imprinted IGF2 allele in TGFalpha induced hepatocellular carcinomas in mice. Oncogene 16:203–209. Heck S, Lezoualc'h F, Engert S, Behl C. (1999) . Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB. J Biol Chem 274:9828–9835. Hellawell GO. (2002). Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62:2942–2950. Henshal DC, Araki T, Schindler CK, Lan JQ, Tiekoter KL, Taki W. (2003). Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuron death. J Neurosci 22:8458-65. Her GM, Yeh YH, Wu JL. (2003). 435-bp liver regulatory sequence in the liver fatty acid binding protein (L-FABP) gene is sufficient to modulate liver regional expression in transgenic zebrafish.Dev Dyn 227:347-56 Hermanto U, Zong CS, Li W, Wang LH. (2002). RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 22:2345–2365. Hill DJ, Strutt B, Arnay E, Zaina S, Coukell S, Graham CF. (2000).Increased and persistent circulating insulin-like growth factor II in neonatal transgenic mice suppresses developmental apoptosis in the pancreatic islets. Endocrinology 141:1151-7. Holgado-Madruga M, Emlet DR, Moscatello DK, et al. (1996). A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 379:560–564. Hong J, Zhang G, Dong F, Rechler MM. (2002). Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277:10489-97. Issa JPJ, Vertino PM, Boehm CD. (1996). Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 93:11757–11762. Jansen M, van Schaik FM, Ricker A. (1983). Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature 306:609–611. Jirtle RL, Hankins GR, Reisenbichler H, Boyer IJ. (1994). Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital. Carcinogenesis 15:1473–1478. Joelle D, Martin H. (2003). Biology of insulin-like growth factors in development. Birth Defects Research (Part C) 69:257–271 Jones JI, Clemmons DR. (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. (2002). Low serum insulin-like growth factor-1 is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106: 939–944. Kaleko M, Rutter WG, Miller AD. (1990). Overexpression of the human insulin like growth factor 1 receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10:464–473. Kermer P, Klocker N, Labes M, Bahr M . (2000) . Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent akt phosphorylation and inhibition of caspase-3 In vivo. J Neurosci 20:722–728. Kiess W, Yang Y, Kessler U. (1994). Insulin-like growth factor II (IGF-II) and the IGF-II mannose-6-phosphate receptor—the myth continues. Hormone Res 41:66–73. Kimmel CB , Ballard WW, Kimmel SR, Ullmann B, Schilling TF. ( 1995).Stage of embryonic development of the zebrafish . Dev Dny 203:253-310. Kim SJ, Park SE, Lee C. (2002). Alterations in promoter usage and expression levels in insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF-II. Biochim Biophys Acta 1586:307–315. Kops GJ and Burgering BM. (2000) . Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J Anat 197 Pt 4l:571–574. Kornfeld S. (1992). Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu Rev Biochem 61:307–330. Kortylewski M, Feld F, Kruger KD, Bahrenberg G, Roth RA, Joost I. (2003). Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J Biol Chem 278:5242-9. Kres IP, Damir B, Jasminka P. (2002 ). The role of insulin-like growth factor 2 and its receptors. Mol Med 8(12):771-80. Lavan BE, Lane WS, Lienhard GE. (1997)A. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family.J Biol Chem 272:11439–11443. Lavan BE, Fantin VR, Chang ET. (1997)B. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem 272:21403–21407. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV, Duncan SA. (2004). Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39(4):1038-47. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. (1995). Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143-163. Leverrier Y, Thomas J, Mathieu AL, Low W, Blanquier B, Marvel J. (1999) . Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells. Cell Death Differ 6: 290–296. Ligensa T, Krauss S, Demuth D. (2001). A PDZ domain protein interacts with the C-terminal tail of the insulinlike growth factor-1 receptor but not with the insulin receptor. J Biol Chem 276:33419–33427. Ligensa T, Krauss S, Demuth D. (2001). A PDZ domain protein interacts with the C-terminal tail of the insulinlike growth factor-1 receptor but not with the insulin receptor. J Biol Chem 276:33419–33427. Lingohr MK, Buettner R, Rhodes CJ. (2002). Pancreatic B-cell growth and survival - a role in obesity-linked type 2 diabetes? Trends Mol Med 8:375-84. Lingohr MK, Dickson LM, Wrede CE, McCuaig JF, Myers MG, Rhodes CJ. (2003). IRS-3 inhibits IRS-2 mediated signaling in pancreatic beta-cells. Moll Cell Endocrinol 204:85-99. Lin SB, Hsieh SH, Hsu HL, Lai MY, Kan L S, Au LC. (1997). Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem (Tokyo) 122:717–722. Liu JP, Baker J, Perkins AS. (1993). Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-I) and type 1 IGF receptor (Igf1r). Cell 75:59–72. Li X, Nong Z, Ekstrom C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekstrom TJ, Schirmacher P. (1997). Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 57:2048–2054. Michael NP , Eva SS, Susan EH. (2004). Insulin like growth factors and neoplasia. Nat Rev Cancer 4(7):505-18. Miyake H, Pollak M, Gleave ME. (2000). Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60:3058–3064. Miyashita T, Reed JC. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299. Monga SPS, Monga HK, Tan X, Mule’K, Pediaditakis P, Michalopoulos GK. (2003).B-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology124:202–216. Moodie SA, Alleman-Sposeto J, Gustafson TA. (1999). Identification of the APS protein as a novel insulin receptor substrate. J Biol Chem 274:11186–11193. Myers MG Jr, Sun XJ, Cheatham B. (1993). IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidylinositol 3’-kinase. Endocrinology 132:1421–1430. Nakae J, Kido Y, Accili D. (2001). Distinct and overlapping functions of insulin and IGF-I receptors. Endoc Re 22:818–835. Nardone G, Romano M, Calabro A, Pedone PV, de Sio I, Persico M, Budillon G, Bruni CB, Riccio A, Zarrilli R. (1996). Activation of foetal promoters of insulin like growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 23:1304–1312. Neckameyer WS, Wang LH. (1985). Nucleotide sequence of avian sarcoma virus UR2 and comparison of its transforming gene with other members of the tyrosine protein kinase oncogene family. J Virol 53:879–884. Nickerson T. (2001). In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61:6276–6280. Norstedt G, Levinovitz A, Moller C, Eriksson LC, Andersson G. (1988). Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat. Carcinogenesis 9:209–213. Oh CD, Chun JS. (2003). Signaling mechanisms leading to the regulation of differentiation and apoptosis of articular chondrocytes by insulin-like growth factor-1. J Biol Chem 278:36563-71. O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD. (2002).Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143, 4287–4294. Patti ME, Sun XJ, Bruening JC. (1995). 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice. J Biol Chem 270:24670–24673. Pelicci G, Lanfrancone L, Grignani F. (1992). A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70:93–104. Pollak M. (2000).Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224–1228 Pollak M. (2001). Insulin-like growth factors (IGFs) and prostate cancer. Epidemiol Rev 23:59–66. Pravtcheva DD, Wise TL. (1998). Metastasizing mammary carcinomas in H19 enhancers IGF2 transgenic mice. J Exp Zoology 281:43–57. Reik W, Constancia M, Dean W. (2000). Igf2 imprinting in developmentand disease. Int J Dev Biol 44:145–150. Resnicoff M, Sell C, Rubini M. (1994). Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54: 2218–2222. Raile K, Höflich A, Kessler U, Yang Y, Pfuender M, Blum WF, Kolb H, Schwarz HP, Kiess W. (1994). Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 159:531–541. Rhodes CJ, White MF. (2002). Molecular insights into insulin action and secretion. Eur J Clin Invest 32(Suppl.3):3-13. Rother KI, Accili D. (2000). Role of insulin receptors and IGF receptors in growth and development. Pediatr Nephrol 14:558–561. Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P, Accili D. (1998). Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem 273:17491-7. Rubin R, Baserga R. (1995). Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73:311–331. Saeki M, Maeda S, Wada K, Kamisaki Y. (2002). Insulin-like growth factor-1 protects peroxynitrite-induced cell death by preventing cytochrome c-induced capase-3 activation. J Cell Biochem 84:708-16. Scharf JG, Dombrowski F, Ramadori G. (2001). The IGF axis and hepatocarcinogenesis. Mol Pathol 54:138–144. Sedlaczek N , Hasilik A, Neuhaus P, Schuppan D , Herbst H. (2003). Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Brith J Cancer 88:733-739. Sherr CJ, Rettenmier CW, Sacca R. (1985). The c-fms proto-oncogene products related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41:665–676. Shuda M, KondohN , Imazeki N , Tanaka K , OkadaT , Mori K ,Hada A ,Arai M ,WakatsukiT , Matsubara O ,Yamamoto N ,Yamamoto M. (2003). Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. Genes Dev 14 2:152-7. Sohda T, Yun K, Iwata K, Soejima H, Okumura M. (1996). Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 75:307–311. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. (2001). Regulation of PTEN transcription by p53. Mol Cell, 8:317-325. Sukmi KP, Lee YI , Young IL. ( 2003 ). PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett 19:545(2-3):203-8. Sun XJ, Rothenberg P, Kahn CR. (1991). Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73–77. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K. (1996). Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Dig Dis Sci 41:208–215. Tennant MK. (1996). Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81:3774–3782. Thissen JP, Ketelslegers JM, Underwood LE. (1994). Nutritional regulation of the insulin-like growth factors. Endo Rev 15:80–101. Toshifumi T,Yasutaka S, Yasuo O, Hiroki K, Yoichi K,Masahiro T. ( 2004 ). Alterations of the M6p/Igf2 receptor gene in hepatocellular carcinomas induced by N-nitrosodiethylamine and a choline-deficient L-amino acid–defined diet in rats. Mol Carcinog 39(4):199-205. Travis M, Chan SJ, Xu B, Sun H, Ding J, Duan C.(2002). Structural, Biochemical, and Expression Analysis of Two Distinct Insulin-Like Growth Factor I Receptors and Their Ligands in Zebrafish. Endocrinology 143:5 1858-1871 Tseng YH, Ueki K, Kriauciunas KM, Kahn CR. (2002). Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. J Biol Chem 277:31601-11. Udvadia AJ, Koster RW,Skene JH. (2001).GAP-43 promoter elements in transgenic zebrafish reveal a difference in signals for axon growth during CNS development and regeneration. Development 128:1175-82. Ullrich A, Bell JR, Chen EY. (1985) .Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313:56–761. Ullrich A, Gray A, Tam AW. (1986). Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 10:2503–2512. Vallee S, Fouchier F, Bremond P, Briand C, Marvaldi J, Champion S. (2003). Insulin-like growth factor-1 downregulates nuclear factor kappa V activation and upregulates interleukin-8 gene expression induced by tumor necrosis factor alpha. Biochem Biophys Res Commun 305:831-9. Vasan RS. (2003). Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infection: the Framingham Heart Study. Ann Intern Med 139:642–648. Veerkamp JH, Maatman RG. (1995).Cytoplasmic fatty acid-binding proteins: their structre and genes. Prog Lipid Res 34:17-52. Von Horn H, Ekstrom C, Ellis E, Olivecrona H, Einarsson C, Tally M. (2002). GH is a regulator of IGF2 promoter-specific transcription in human liver. J Endocrinol 172:457-65. Vu TH, Hoffman AR. (1994). Promoter-speci.c imprinting of the human insulin-like growth factor-II gene. Nature 371:714–717. Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P. (1999). Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 68:161–181. White MF, Kahn CR. (1994). The insulin signaling system. J Biol Chem 269:1–4. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S. (1998). Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-4. Withers DJ, White M. (2002). Perspective: The insulin signaling system - a common link in the pathogenesis of type 2 diabetes. Endocrinology 141:1917-21. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. (2002). Circulating insulin-like growth factor-1 levels regulate colon cancer growth and metastasis. Cancer Res. 62:1030–1035. Wylie AA, Pulford DJ, McVie-Wylie AJ. (2003). Tissue-specific inactivation of murine M6P/IGF2R.AmJ Pathol 162:321–328. Xiaoming Y, Hu JF, Mark D, Hadas S, Xiangjun Z, Huifan Y, Lu H, Zhilan Z, Qingxue W, Li T, Andrew RH. ( 2003 ). A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. Clin Invest 111(2):265-73. Yamada T, De Souza AT, Finkelstein S, Jirtle RL. (1997). Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 94:10 351–10 355. Yamaguchi A, Tamatani M,Matsuzaki H. (2001). Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptinal activity of p53. J Biol Chem 276:5256–5264. Yang-Feng Y, Ullrich A, Francke U. (1985). Gene for human insulin receptor: localization to site on chromosome 19 involved in pre-B-cell leukemia. Science 228:728–731. Zhang L. (1997). Gene expression profiles in normal and cancer cells. Science 276:1268–1272. Zhan S, Shapiro D, Zhan S. (1995). Concordant loss of imprinting of the human insulin-like growth factor II gene. J Biol Chem 270:27983–27986. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34952 | - |
| dc.description.abstract | 中文摘要
第二形類胰島素因子 (IGF-II)，是刺激細胞分裂分化的一個重要的原素，且在胚胎發育上扮演一個重要的角色。大部分的IGFs由肝臟生產藉由與類胰島素因子結合蛋白(IGFBPs)構成一個複合蛋白然後釋放到血液中在生物體內循環。在先前的研究中指出，IGF-2通常會被基因印痕(genomic imprinting)抑制其表現。但是，IGF-2經常由腫瘤和腫瘤細胞株所分泌，尤其是在肝癌中，在肝臟硬化的早期機制中，通常會伴隨著IGF-2表現量的增加，特別是在由HBV和HCV引起的慢性肝癌。由於IGF-2的大量表現與肝癌的發生有著相當密切的關係，所以本篇論文嘗試設計在斑馬魚的肝臟中過量表現IGF-2，並針對其下游因子以及受到過量表現IGF-2影響的肝臟的型態加以分析。 在結果中發現，過量表現IGF-2 將引起肝臟異常肥大，而且細胞的型態也與對照組不同，在分析其下游基因後發現，抗細胞凋亡基因群及促細胞週期基因群都會受到IGF-2的正調控，從這些的結果中指出，在肝臟中過量表現IGF-2極有可能可以發展成肝癌。在將來的實驗上可以利用這樣的轉殖基因魚，使其成為一個易於誘發肝癌的疾病模式。 | zh_TW |
| dc.description.abstract | Abstract
Insulin-like growth factor-2 (IGF-II), mainly synthesized in liver then transport to target tissues through endocrine system, is an important factor that stimulate cell proliferation, differentiation and division, promote organ development and play as a survival factor in apoptosis. However, the functional role of liver-derived IGF-II before partum still remains unclear. In this study, we use liver fatty acid binding protein (L-FABP) promoter to drive IGF-II expression in a liver-specific manner. To facilitate the direct imaging of liver development, constructs containing expression cascade were introduced to one-cell stage embryo of transgenic zebrafish lines bearing liver-specific GFP expression. Exogenous IGF-2 expression is first detected at 34hpf under the control of LFABP promoter. Obvious liver enlargement was observed at 10dpf and continues to grow; gut tube was pushed up by the enlarged liver but appears un-disrupted morphologically. At 17dpf, the volume of IGF-2 over-expressed liver is 1.5 times bigger statistically than the wild-type control using confocal microscopy. The increased number and enlarged hepatocyte cell shape were also observed under confocal microscopy examination. We further use PT-PCR to monitor molecular, which may involve in this phenomena. IGF-binding protein, IGFBP1 and IGFBP3 were down-regulated; Cell cycle related gene such as c-myc, cyclin-D1, gankyrin; anti-apoptosis genes such as bcl-xl and liver-enriched transcription factors such as HNF4αand HNF1αwere up-regulated suggesting the rapid cell division leading to increase cell number were controlled by hepatic program and anti-apoptosis genes. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T06:37:29Z (GMT). No. of bitstreams: 1 ntu-94-R90243018-1.pdf: 1630968 bytes, checksum: ecb20226a902e72ac710a45d2167074e (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 目錄
中文摘要 1 英文摘要 2 壹、前言 3 貳、研究架構 16 參、實驗材料 17 一、生物材料 17 二、儀器及器材 17 三、反應試劑 18 肆、實驗方法 32 伍、實驗結果 47 陸、討論 54 柒、參考文獻 62 捌、圖表 77 | |
| dc.language.iso | zh-TW | |
| dc.title | 在肝臟中專一性過量表現第二型類胰島素因子將導致肝臟不正常的增生 | zh_TW |
| dc.title | Liver-Specific Overexpression of igf-2 Leads to Liver hypertrophy | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃聲蘋,洪健睿,何國牟,李士傑 | |
| dc.subject.keyword | 第二型類胰島素因子,肝癌, | zh_TW |
| dc.subject.keyword | igf-2,Liver hypertrophy, | en |
| dc.relation.page | 97 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-10-04 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 漁業科學研究所 | zh_TW |
| 顯示於系所單位： | 漁業科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 目前未授權公開取用 | 1.59 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。